• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk

    Simply Wall St·07/11/2026 11:30:29
    语音播报

    ImmunityBio (IBRX) is back in focus after several investment firms disclosed new positions in the stock, along with active trader speculation around a possible Q2 revenue surprise and upcoming Anktiva label expansion updates.

    See our latest analysis for ImmunityBio.

    At around $8.22, ImmunityBio’s recent pullback, with a 1-day share price return of down 7.33% and 7-day share price return of down 12.92%, follows a sharp year-to-date share price return of 306.93% and a 1-year total shareholder return of 192.53%. This suggests enthusiasm has cooled slightly as traders reassess the impact of potential Q2 revenue news and Anktiva label updates.

    If you are looking beyond ImmunityBio for other healthcare opportunities tied to AI and data, this could be a useful moment to scan 41 healthcare AI stocks

    ImmunityBio now trades well below the average analyst target and implied intrinsic value, even after a very large 1-year move. The next section examines where fair value might realistically sit along that range.

    Most Popular Narrative: 36.8% Undervalued

    Based on the most followed narrative, ImmunityBio’s fair value of $13 sits well above the last close at $8.22, putting a spotlight on what assumptions justify that gap.

    The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

    The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.

    Read the complete narrative.

    Want to see how this global rollout and post checkpoint positioning feed into the $13 fair value? Revenue scaling, margin lift, and a premium future earnings multiple sit at the heart of this narrative. Curious how those pieces are stitched together across the next few years? The full story breaks down the specific growth path behind that valuation call.

    Result: Fair Value of $13 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the ImmunityBio story also carries clear pressure points, particularly the concentration in ANKTIVA for bladder cancer and the risk that regulators limit label expansions.

    Find out about the key risks to this ImmunityBio narrative.

    Next Steps

    With ImmunityBio carrying both clear risks and appealing potential rewards, it makes sense to move quickly and check the underlying data yourself. To see how those trade offs stack up in one place, review the 3 key rewards and 2 important warning signs

    Looking for more investment ideas beyond ImmunityBio?

    Once you have weighed up ImmunityBio, do not stop there. Broaden your watchlist with other focused stock ideas that could help sharpen your overall portfolio decisions.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.